10 November 2026
Sidley Represents Sino Biopharmaceutical in its US$7 Billion Licensing Agreement With Boehringer Ingelheim
Advising firms
Deal team
7 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Lila Hope Lead | Sidley | Partner | Technology and Life Sciences Transactions | Not stated |
| Ruchun Ji | Sidley | Not stated | M&A | Not stated |
| Jennifer Raab | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Jean Qiu | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Collin Marshall | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Yuhan Wu | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Chen Yang | Sidley | Not stated | Food, Drug and Medical Device | Not stated |
4 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 7bn (US$7 Billion)
- What the figure measures
- Total transaction value
- Client
- Sino Biopharmaceutical LimitedIssuer
- Counterparties
- Boehringer Ingelheim (Investor)